https://pharmadevicenews.com/can-virions-t-cell-immunotherapy-help-achieve-a-functional-hepatitis-b-cure/ PharmaDeviceNews en 2026-10-17T16:30:19+00:00 Can Virion’s T-cell immunotherapy help achieve a functional hepatitis B cure? AASLD 2026, Andrew Luber, chronic hepatitis B, Edward Gane, elebsiran, Grace Lai-Hung Wong, HBV functional cure, Hepatitis B Surface Antigen, Nucleoside Analogues, T-Cell Immunotherapy, The Lancet Microbe, The Liver Meeting, Tobevibart, Virion Therapeutics, VRON-0200 https://pharmadevicenews.com/wp-content/uploads/2025/12/chronic-hepatitis-B-infection.webp https://pharmadevicenews.com/palleon-to-present-hlx79-and-rituximab-combination-data-at-acr-convergence-2026/ PharmaDeviceNews en 2026-10-17T16:26:54+00:00 Palleon to present HLX79 and rituximab combination data at ACR Convergence 2026 ACR Convergence 2026, ASN Kidney Week, autoimmune kidney disease, Carolyn Bertozzi, E-602, Glycan Editing, HANLIKANG, HLX01, HLX79, Jim Broderick, Membranous Nephropathy, Palleon Pharmaceuticals, rituximab, Shanghai Henlius Biotech, Sialidase https://pharmadevicenews.com/wp-content/uploads/2026/09/Nephropathy-research-e1790188192921.webp https://pharmadevicenews.com/chipscreen-secures-china-trial-approval-for-pd-l1-targeted-epigenetic-antibody-conjugate/ PharmaDeviceNews en 2026-10-17T08:09:02+00:00 Chipscreen secures China trial approval for PD-L1-targeted epigenetic antibody conjugate advanced solid tumors, AI-ChemGen, Antibody Conjugates, Chidamide, China, Chipscreen Biosciences, Chipscreen Newway Biosciences, Epidaza, Epigenetic Immunotherapy, histone deacetylase inhibitors, immunotherapy resistance, NMPA, NW001, PD-L1 https://pharmadevicenews.com/wp-content/uploads/2026/01/antibody-targeted-therapy-in-lymphoma-treatment.webp https://pharmadevicenews.com/cofactors-oncoprism-predicts-71-immunotherapy-response-in-lung-cancer-subgroup/ PharmaDeviceNews en 2026-10-17T08:04:20+00:00 Cofactor’s OncoPrism predicts 71% immunotherapy response in lung cancer subgroup Cofactor Genomics, Gene Expression Classifiers, Genentech, Howard Bailey, immune checkpoint inhibitors, Jarret Glasscock, Kevin Flanagan, non-small cell lung cancer, OAK Trial, OncoPrism-HNSCC, OncoPrism-NSCLC, PD-L1, precision oncology, PREDAPT, RNA Sequencing https://pharmadevicenews.com/wp-content/uploads/2026/08/Lung-cancer-study-e1787082418957.webp https://pharmadevicenews.com/immunitybio-reports-84-three-year-bladder-preservation-among-anktiva-responders/ PharmaDeviceNews en 2026-10-17T07:59:30+00:00 ImmunityBio reports 84% three-year bladder preservation among ANKTIVA responders Altor BioScience, ANKTIVA, Bacillus Calmette-Guérin, carcinoma in situ, cystectomy, FDA, ImmunityBio, Journal of Urology, nogapendekin alfa inbakicept, non-muscle-invasive bladder cancer, Patrick Soon-Shiong, QUILT-3.032, Richard Adcock https://pharmadevicenews.com/wp-content/uploads/2026/07/ImmunityBio-secures-broad-UAE-authorization-for-ANKTIVA-in-bladder-and-lung-cancer-e1785384506177.webp https://pharmadevicenews.com/emeranova-partners-with-halo-biosystems-for-hyaluronic-acid-wound-technology/ PharmaDeviceNews en 2026-10-17T05:51:53+00:00 EmeraNova partners with Halo Biosystems for hyaluronic acid wound technology Andrew Dunn, BioLab Holdings, Burns, diabetic foot ulcers, EmeraNova, FDA, Halo Biosystems, HYAFF 11, Hyalomatrix, hyaluronic acid, Jaime Leija, Kent Imaging, Pressure Ulcers, Sweet Bio, Tissue Restoration, wound care https://pharmadevicenews.com/wp-content/uploads/2026/10/EmeraNova-partners-with-Halo-Biosystems-to-expand-Hyalomatrix-wound-care-access-scaled-e1792216260303.webp https://pharmadevicenews.com/alcons-new-eye-drops-last-up-to-12-hours-can-brytly-challenge-lumify/ PharmaDeviceNews en 2026-10-17T05:46:02+00:00 Alcon’s new eye drops last up to 12 hours. Can BRYTLY challenge Lumify? Alcon, Alpha Adrenergic Agonists, Apraclonidine, Bausch + Lomb, Brimonidine, BRYTLY, Consumer Eye Care, Eye Redness, FDA, Jonathan Balch, Lumify, ophthalmology, over-the-counter medicines, Systane https://pharmadevicenews.com/wp-content/uploads/2026/10/Alcon-BRYTLY-targets-redness-relief-within-one-minute-of-application-scaled-e1792215892639.webp https://pharmadevicenews.com/pelages-hair-loss-drug-showed-a-31-early-response-rate-can-600-patients-confirm-it/ PharmaDeviceNews en 2026-10-17T05:40:43+00:00 Pelage’s hair-loss drug showed a 31% early response rate. Can 600 patients confirm it? androgenetic alopecia, ARCH Venture Partners, AWAKEN, Christina Weng, Daniel Gil, FDA, finasteride, GV, Hair Follicle Stem Cells, minoxidil, Norwood-Hamilton Scale, Pelage Pharmaceuticals, PP405, regenerative medicine https://pharmadevicenews.com/wp-content/uploads/2026/04/Nektars-alopecia-areata-catalyst-is-here-what-52-week-rezpegaldesleukin-data-could-mean-for-Phase-3-e1776663142113.webp https://pharmadevicenews.com/one-antibody-could-target-both-eczema-inflammation-and-itching-zai-labs-first-human-results-are-coming/ PharmaDeviceNews en 2026-10-17T04:57:28+00:00 One antibody could target both eczema inflammation and itching. Zai Lab’s first human results are coming ACAAI 2026, American College of Allergy Asthma and Immunology, atopic dermatitis, bispecific antibodies, Dupilumab, Dupixent, Ebglyss, FDA, interleukin-13, Interleukin-31 Receptor Alpha, lebrikizumab, Nemluvio, nemolizumab, Rafael Amado, Zai Lab, ZL-1503 https://pharmadevicenews.com/wp-content/uploads/2026/06/Chronic-hand-eczemas-hidden-cost-emerges-in-DELTA-FORCE-and-DELTA-TEEN-data-e1782663756589.webp https://pharmadevicenews.com/four-of-eight-pancreatic-cancer-patients-responded-to-vs-7375-can-verastem-repeat-the-result-in-phase-3/ PharmaDeviceNews en 2026-10-17T04:54:09+00:00 Four of eight pancreatic cancer patients responded to VS-7375. Can Verastem repeat the result in Phase 3? colorectal cancer, Daniel Paterson, FDA, GenFleet Therapeutics, GFH375, KRAS G12D, Michael Kauffman, non-small cell lung cancer, pancreatic ductal adenocarcinoma, TARGET-D 101, TARGET-D 201, TARGET-D 202, TARGET-D 203, Verastem Oncology, VS-7375 https://pharmadevicenews.com/wp-content/uploads/2026/05/Phanes-Therapeutics-spevatamig-posts-updated-Phase-2-data-in-first-line-metastatic-PDAC-e1780037386443.webp https://pharmadevicenews.com/pfizers-lyme-vaccine-showed-73-efficacy-but-missed-a-statistical-hurdle-what-comes-next/ PharmaDeviceNews en 2026-10-17T04:51:05+00:00 Pfizer’s Lyme vaccine showed 73% efficacy, but missed a statistical hurdle. What comes next? ABRYSVO, BioNTech, COMIRNATY, IDWeek 2026, LB6V, Lyme disease, PAXLOVID, PENBRAYA, PF-07307405, PF-07872412, Pfizer, Pneumococcal Disease, Prevnar 20, respiratory syncytial virus, Valneva, VALOR https://pharmadevicenews.com/wp-content/uploads/2026/05/Modernas-hantavirus-vaccine-signal-exposes-the-next-test-for-mRNA-confidence-e1778345794941.webp https://pharmadevicenews.com/a-simple-injection-cut-a-key-alzheimers-protein-by-73-can-arrowhead-turn-that-into-cognitive-benefit/ PharmaDeviceNews en 2026-10-16T16:50:08+00:00 A simple injection cut a key Alzheimer’s protein by 73%. Can Arrowhead turn that into cognitive benefit? Adam Boxer, Alzheimer’s disease, ARO-MAPT, ARO-MAPT-SC, Arrowhead Pharmaceuticals, Biogen, CELIA Study, Christopher Anzalone, Diranersen, frontotemporal dementia, Ionis Pharmaceuticals, MAPT, Progressive Supranuclear Palsy, RNA interference, Tau Protein, TRiM, University of California San Francisco https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Alzheimers-generic.webp https://pharmadevicenews.com/pilatus-biosciences-doses-first-hong-kong-patient-in-plt012-liver-cancer-trial/ PharmaDeviceNews en 2026-10-16T16:45:40+00:00 Pilatus Biosciences doses first Hong Kong patient in PLT012 liver cancer trial Cancer Research Institute, CD36, FDA, hepatocellular carcinoma, Hong Kong Department of Health, Ludwig Institute for Cancer Research, Novotech, Pilatus Biosciences, PLT012, Prince of Wales Hospital, Raven Lin, Stephen Chan, The Chinese University of Hong Kong https://pharmadevicenews.com/wp-content/uploads/2026/07/AbelZetas-C-CAR031-Nature-study-strengthens-the-case-for-armored-CAR-T-in-advanced-liver-cancer-e1785037227142.webp https://pharmadevicenews.com/ironfists-tamrada-more-than-doubles-survival-in-preclinical-pancreatic-cancer-model/ PharmaDeviceNews en 2026-10-16T16:41:42+00:00 Ironfist’s Tamrada more than doubles survival in preclinical pancreatic cancer model copper-64, EANM 2026, Ironfist Therapeutics, Jeffrey Cleland, Johns Hopkins University, Lutetium-177, Mukul Agarwal, pancreatic ductal adenocarcinoma, PD-1 inhibitors, radiopharmaceuticals, Sakura Minami, Tamrada, theranostics, Tumor-Associated Macrophages https://pharmadevicenews.com/wp-content/uploads/2026/05/ClearNote-Health-to-present-Avantect-pancreatic-cancer-test-validation-data-at-ASCO-2026-e1779559031969.webp https://pharmadevicenews.com/akamis-bio-completes-33-patient-ng-350a-rectal-cancer-trial-after-early-50-response/ PharmaDeviceNews en 2026-10-16T15:18:00+00:00 Akamis Bio completes 33-patient NG-350A rectal cancer trial after early 50% response Akamis Bio, Capecitabine, CD40 agonist, CEDAR, chemoradiotherapy, circulating tumor DNA, colorectal cancer, Fast Track designation, FDA, FORTRESS, Mismatch Repair-Proficient Colorectal Cancer, NG-350A, Oliver Rosen, Rectal Cancer, T-SIGn https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-14-2026-09_35_09-AM-e1789358748685.webp https://pharmadevicenews.com/coyas-als-trial-has-enrolled-120-patients-why-is-it-extending-coya-302-treatment-before-results-arrive/ PharmaDeviceNews en 2026-10-16T15:14:50+00:00 Coya’s ALS trial has enrolled 120 patients. Why is it extending COYA 302 treatment before results arrive? ALSFRS-R, ALSTARS, amyotrophic lateral sclerosis, Arun Swaminathan, COYA 302, Coya Therapeutics, CTLA-4 Ig, Dr. Reddy’s Laboratories, Fast Track designation, FDA, Fred Grossman, frontotemporal dementia, interleukin-2, regulatory T cells https://pharmadevicenews.com/wp-content/uploads/2026/01/neurological-basis-of-amyotrophic-lateral-sclerosis.webp https://pharmadevicenews.com/one-blood-sample-68000-possible-pathogens-can-delve-bio-speed-up-infection-diagnosis/ PharmaDeviceNews en 2026-10-16T14:54:40+00:00 One blood sample, 68,000 possible pathogens: Can Delve Bio speed up infection diagnosis? Brad Murray, CAP, Charles Chiu, CLIA, Delve Bio, Delve Decide, Delve Detect, Delve Detect Plasma, IDWeek 2026, immunocompromised patients, infectious disease diagnostics, metagenomic next-generation sequencing, molecular diagnostics, University of California San Francisco https://pharmadevicenews.com/wp-content/uploads/2026/07/Blood-test.webp https://pharmadevicenews.com/nemolizumab-improved-itching-and-sleep-for-a-year-in-young-children-can-galderma-expand-its-fda-label/ PharmaDeviceNews en 2026-10-16T06:52:53+00:00 Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label? ARCADIA, atopic dermatitis, Christophe Piketty, Dupilumab, Dupixent, FDA, Galderma, IL-31 Receptor Alpha, Interleukin-31, Lawrence Eichenfield, Nemluvio, nemolizumab, Pediatric Dermatology Research Alliance, PeDRA 2026 https://pharmadevicenews.com/wp-content/uploads/2026/03/Galderma-presents-pediatric-nemolizumab-findings-at-AAD-2026-as-regulatory-case-builds-for-under-12-label-e1774759149703.webp https://pharmadevicenews.com/gilead-is-betting-nearly-1-9bn-on-masked-cancer-drugs-what-makes-virs-technology-different/ PharmaDeviceNews en 2026-10-16T04:39:20+00:00 Gilead is betting nearly $1.9bn on masked cancer drugs. What makes Vir’s technology different? Amunix Pharmaceuticals, Astellas Pharma, cancer immunotherapy, dAIsY, Flavius Martin, Gilead Sciences, Marianne De Backer, PRO-XTEN, Sanofi, solid tumors, T-cell engagers, Vir Biotechnology, VIR-5500, VIR-5525, VIR-5818 https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/the-fda-rejected-tab-cel-twice-can-ataras-third-review-finally-deliver-approval/ PharmaDeviceNews en 2026-10-16T04:34:22+00:00 The FDA rejected tab-cel twice. Can Atara’s third review finally deliver approval? ALLELE, allogeneic T-cell therapy, Atara Biotherapeutics, Cokey Nguyen, EBVALLO, Epstein-Barr virus, European Medicines Agency, FDA, Pierre Fabre Laboratories, Post-Transplant Lymphoproliferative Disease, Tab-cel, tabelecleucel https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png